Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 74, Issue 1

Antifungal activity of 2-adamantylamine hydrochloride on and No Access

Graphical Abstract

Graphical abstract

Abstract

Increased virulence and drug resistance in species of resulted in reduced disease control and further demand the development of potent antifungal drugs.

The repurposing of non-antifungal drugs and combination therapy has become an attractive alternative to counter the emerging drug resistance and toxicity of existing antifungal drugs against and non-albicans species.

This study aimed to accelerate antifungal drug development process by drug repurposing approach.

In this study, the antifungal effects of the antiviral drug, 2-adamantylamine hydrochloride (2-AM), were explored against and . Broth microdilution measured efficacy of 2-AM, whereas reactive oxygen species (ROS) accumulation and ergosterol quantification, cell cycle and phosphatidylserine externalization studies were detailed to investigate the antifungal mode of 2-AM action.

Results showed that 2-AM had fungicidal action against both the strains where, 2-AM further inhibited morphogenic transitions as well. Antibiofilm action of 2-AM on was evidenced on urinary catheters. G2/M phase arrest and apoptosis indicated ROS induced antifungal effect of 2-AM on both strains.

Results of studies offers insight into the antifungal activity of 2-AM and may serve as an effective antifungal repurposed candidate against and .

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): 2-adamantylamine hydrochloride , apoptosis , Candida , drug repurposing , ergosterol , fungal biofilm and ROS
Funding
This study was supported by the:
  • University Grants Commission (Award 855/(CSIR-UGC NET DEC.2017))
    • Principal Award Recipient: TanjilaGavandi
© 2025 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001943
2025-01-29
2026-01-17

Metrics

Loading full text...

Full text loading...

References

  1. Gómez-Gaviria M, Ramírez-Sotelo U, Mora-Montes HM. Non-albicans Candida species: immune response, evasion mechanisms, and new plant-derived alternative therapies. J Fungi 2023; 9:11 [View Article]
     [Google Scholar]
  2. Abdel-Hamid RM, El-Mahallawy HA, Abdelfattah NE, Wassef MA. The impact of increasing non-albicans Candida trends on diagnostics in immunocompromised patients. Braz J Microbiol 2023; 54:2879–2892 [View Article]
     [Google Scholar]
  3. Xu Y, Wang Y, Yan L, Liang R-M, Dai B-D et al. Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: endogenous ROS augmentation. J Proteome Res 2009; 8:5296–5304 [View Article] [PubMed]
     [Google Scholar]
  4. Branco J, Miranda IM, Rodrigues AG. Candida parapsilosis virulence and antifungal resistance mechanisms: a comprehensive review of key determinants. J Fungi 2023; 9:80 [View Article]
     [Google Scholar]
  5. Candida auris StatPearls - NCBI Bookshelf. n.d https://www.ncbi.nlm.nih.gov/books/NBK563297/
  6. Ajetunmobi OH, Wall G, Vidal Bonifacio B, Martinez Delgado LA, Chaturvedi AK et al. High-throughput screening of the Repurposing Hub library to identify drugs with novel inhibitory activity against Candida albicans and Candida auris biofilms. J Fungi 2023; 9:879 [View Article]
     [Google Scholar]
  7. Haque F, Alfatah M, Ganesan K, Bhattacharyya MS. Inhibitory effect of sophorolipid on Candida albicans biofilm formation and hyphal growth. Sci Rep 2016; 6:23575 [View Article] [PubMed]
     [Google Scholar]
  8. Ramage G, Saville SP, Wickes BL, López-Ribot JL. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 2002; 68:5459–5463 [View Article] [PubMed]
     [Google Scholar]
  9. Eldesouky HE, Salama EA, Li X, Hazbun TR, Mayhoub AS et al. Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant Candida species. Sci Rep 2020; 10:7525 [View Article] [PubMed]
     [Google Scholar]
  10. Zhang Q, Liu F, Zeng M, Mao Y, Song Z. Drug repurposing strategies in the development of potential antifungal agents. Appl Microbiol Biotechnol 2021; 105:5259–5279 [View Article] [PubMed]
     [Google Scholar]
  11. Gavandi TC, Basrani ST, Chougule SA, Patil SB, Nille OS et al. Vidarabine as a novel antifungal agent against Candida albicans: insights on mechanism of action. Int Microbiol 2024 [View Article] [PubMed]
     [Google Scholar]
  12. Lafleur MD, Sun L, Lister I, Keating J, Nantel A et al. Potentiation of azole antifungals by 2-adamantanamine. Antimicrob Agents Chemother 2013; 57:3585–3592 [PubMed]
     [Google Scholar]
  13. Soliman SSM, Semreen MH, El-Keblawy AA, Abdullah A, Uppuluri P et al. Assessment of herbal drugs for promising anti-Candida activity. BMC Complement Altern Med 2017; 17:257 [View Article] [PubMed]
     [Google Scholar]
  14. Cantón E, Pemán J, Viudes A, Quindós G, Gobernado M et al. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn Microbiol Infect Dis 2003; 45:203–206 [View Article] [PubMed]
     [Google Scholar]
  15. Gong Y, Liu W, Huang X, Hao L, Li Y et al. Antifungal activity and potential mechanism of N-butylphthalide alone and in combination with fluconazole against Candida albicans. Front Microbiol 2019; 10:1461 [View Article] [PubMed]
     [Google Scholar]
  16. Klepser ME, Ernst EJ, Lewis RE, Ernst ME, Pfaller MA. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob Agents Chemother 1998; 42:1207–1212 [View Article] [PubMed]
     [Google Scholar]
  17. Park YK, Shin J, Lee HY, Kim HD, Kim J. Development of carbazole derivatives compounds against Candida albicans: candidates to prevent hyphal formation via the Ras1-MAPK pathway. JoF 2021; 7:688 [View Article]
     [Google Scholar]
  18. Li Y, Jiao P, Li Y, Gong Y, Chen X et al. The synergistic antifungal effect and potential mechanism of D-penicillamine combined with fluconazole against Candida albicans. Front Microbiol 2019; 10: [View Article]
     [Google Scholar]
  19. Agarwalla SV, Ellepola K, Silikas N, Castro Neto AH, Seneviratne CJ et al. Persistent inhibition of Candida albicans biofilm and hyphae growth on titanium by graphene nanocoating. Dent Mater 2021; 37:370–377 [View Article] [PubMed]
     [Google Scholar]
  20. Prasath KG, Sethupathy S, Pandian SK. Proteomic analysis uncovers the modulation of ergosterol, sphingolipid, and oxidative stress pathways by myristic acid impeding biofilm and virulence in Candida albicans. J Proteomics 2019; 208:103503 [View Article] [PubMed]
     [Google Scholar]
  21. Arthington-Skaggs BA, Jradi H, Desai T, Morrison CJ. Quantitation of ergosterol content: novel method for determination of fluconazole susceptibility of Candida albicans. J Clin Microbiol 1999; 37:3332–3337 [View Article] [PubMed]
     [Google Scholar]
  22. Jia C, Zhang J, Yu L, Wang C, Yang Y et al. Antifungal activity of coumarin against Candida albicans is related to apoptosis. Front Cell Infect Microbiol 2018; 8:445 [View Article] [PubMed]
     [Google Scholar]
  23. Chatterjee A, Nagarajan H, Padmanabhan P, Vetrivel U, Therese KL et al. Understanding the uptake mechanism and interaction potential of the designed peptide and preparation of composite fiber matrix for fungal keratitis. ACS Omega 2020; 5:12090–12102 [View Article] [PubMed]
     [Google Scholar]
  24. Li Y, Yang J, Li X, Su S, Chen X et al. The effect of ginkgolide B combined with fluconazole against drug-resistant Candida albicans based on common resistance mechanisms. Int J Antimicrob Agents 2020; 56:106030 [View Article]
     [Google Scholar]
  25. Rosato A, Altini E, Sblano S, Salvagno L, Maggi F et al. Synergistic activity of new diclofenac and essential oils combinations against different Candida spp. Antibiotics 2021; 10:1–10 [View Article] [PubMed]
     [Google Scholar]
  26. Li Y, Shan M, Yan M, Yao H, Wang Y et al. Anticandidal activity of kalopanaxsaponin A: effect on proliferation, cell morphology, and key virulence attributes of Candida albicans. Front Microbiol 2019; 10: [View Article]
     [Google Scholar]
  27. Phillips AJ, Sudbery I, Ramsdale M. Apoptosis induced by environmental stresses and amphotericin B in Candida albicans. Proc Natl Acad Sci USA 2003; 100:14327–14332 [View Article] [PubMed]
     [Google Scholar]
  28. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother 2006; 50:2892–2894 [View Article] [PubMed]
     [Google Scholar]
  29. Alvendal C, Mohanty S, Bohm-Starke N, Brauner A. Anti-biofilm activity of chlorhexidine digluconate against Candida albicans vaginal isolates. PLoS One 2020; 15:e0238428 [View Article] [PubMed]
     [Google Scholar]
  30. Kulkarni VS, Alagarsamy V, Solomon VR, Jose PA, Murugesan S. Drug repurposing: an effective tool in modern drug discovery. Russ J Bioorg Chem 2023; 49:157–166 [View Article]
     [Google Scholar]
  31. DAVIES WL, GRUNERT RR, HAFF RF, MCGAHEN JW, NEUMAYER EM et al. Antiviral activity of 1-adamantanamine (amantadine). Science 1964; 144:862–863 [View Article] [PubMed]
     [Google Scholar]
  32. Lafleur MD, Sun L, Lister I, Keating J, Nantel A et al. Potentiation of azole antifungals by 2-adamantanamine. Antimicrob Agents Chemother 2013; 57:3585–3592 [View Article] [PubMed]
     [Google Scholar]
  33. Abirami G, Alexpandi R, Durgadevi R, Kannappan A, Veera Ravi A. Inhibitory effect of morin against Candida albicans pathogenicity and virulence factor production: an in vitro and in vivo approach. Front Microbiol 2020; 11: [View Article]
     [Google Scholar]
  34. Tsopmene UJ, Tokam Kuaté CR, Kayoka-Kabongo PN, Bisso BN, Metopa A et al. Antibiofilm activity of curcumin and piperine and their synergistic effects with antifungals against Candida albicans clinical isolates. Scientifica 2024; 2024:2025557 [View Article] [PubMed]
     [Google Scholar]
  35. Ahamad I, Bano F, Anwer R, Srivastava P, Kumar R et al. Antibiofilm activities of biogenic silver nanoparticles against Candida albicans. Front Microbiol 2021; 12:741493 [View Article] [PubMed]
     [Google Scholar]
  36. Sun C-Q, Peng J, Yang L-B, Jiao Z-L, Zhou L-X et al. A cecropin-4 derived peptide C18 inhibits Candida albicans by disturbing mitochondrial function. Front Microbiol 2022; 13:872322 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001943
Loading
Antifungal activity of 2-adamantylamine hydrochloride on Candida albicans and Candida parapsilosis
J. Med. Microbiol. 74, 001943 (2025); https://doi.org/10.1099/jmm.0.001943
/content/journal/jmm/10.1099/jmm.0.001943
/content/journal/jmm/10.1099/jmm.0.001943
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error